Clinical Trial Detail

NCT ID NCT02298959
Title Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

Advanced Solid Tumor

colorectal cancer

ovarian cancer

melanoma

renal cell carcinoma

Therapies

Aflibercept + Pembrolizumab

Age Groups: adult

No variant requirements are available.